AI Summary
StalkDRUG is in a Stage 4 decline with price below all major EMAs and the 50-DMA. Recent bounce into moving averages has not reclaimed resistance and underscores seller control. Intermediate structure favors further downside, but short-term timing is neutral due to oversold conditions. Selling into EMA and DMA resistance zones remains the preferred approach, with a decisive break above the 21-EMA and 50-DMA on strong volume required to invalidate the bearish thesis.
| METRIC | TREND |
|---|---|
| Sales, Adj. | — |
| YoY % | |
| P / Sales | |
| EV / Sales | |
| Gross Profit, Adj. | — |
| YoY % | |
| Margin % | |
| EV / Gross Profit | |
| EBITDA, Adj. | — |
| YoY % | |
| Margin % | |
| EV / EBITDA | |
| EBIT | — |
| YoY % | |
| Margin % | |
| EV / EBIT | |
| Net Income | — |
| YoY % | |
| Net Margin | |
| EPS (GAAP) | — |
| YoY % |